UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
X QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended July 1, 2007
OR
TRANSITION REPORT
PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition
period from________to_______
COMMISSION FILE
NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235
East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip
code)
(212) 573-2323
(Registrant's telephone number)
Indicate by check mark whether the registrant (1) has
filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports) and (2)
has been subject to such filing requirements for the past 90 days.
YES X NO
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, or a non-accelerated filer. See
definition of "accelerated filer and large accelerated filer" in
Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer X
Accelerated filer Non-accelerated
filer
Indicate by check mark whether the registrant is a shell
company (as defined in Rule 12b-2 of the Exchange Act).
YES NO X
At August 1, 2007, 6,927,108,833 shares of the issuer's
voting common stock were outstanding.
FORM 10-Q
For the Quarter
Ended
July 1, 2007
Table
of Contents
PART I. FINANCIAL
INFORMATION
Page
Item 1.
Financial Statements
Condensed
Consolidated Statements of Income for the three months and six months ended July
1, 2007, and July 2, 2006
Condensed
Consolidated Balance Sheets as of July 1, 2007, and December 31, 2006
Condensed
Consolidated Statements of Cash Flows for the six months ended July 1,
2007, and July 2, 2006
Notes to
Condensed Consolidated Financial Statements
Review Report
of Independent Registered Public Accounting Firm
18
Item 2.
Management's
Discussion and Analysis of Financial Condition and Results of Operations
19
Item 3.
Quantitative
and Qualitative Disclosures About Market Risk
48
Item 4.
Controls and
Procedures
49
PART II. OTHER
INFORMATION
Item 1.
Legal
Proceedings
49
Item 1A.
Risk Factors
51
Item 2.
Unregistered
Sales of Equity Securities and Use of Proceeds
52
Item 3.
Defaults Upon
Senior Securities
52
Item 4.
Submission of
Matters to a Vote of Security Holders
52
Item 5.
Other
Information
52
Item 6.
Exhibits
53
Signature
54
PART
I - FINANCIAL INFORMATION
Item 1. Financial Statements.
PFIZER INC AND
SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three
Months Ended
Six
Months Ended
(millions, except per common share
data)
July 1,
2007
July 2,
2006
July 1,
2007
July 2,
2006
Revenues
11,084
11,741
23,558
23,488
Costs and expenses:
Cost of sales(a)
2,109
1,790
3,996
3,461
Selling,
informational and administrative expenses(a)
3,844
3,881
7,205
7,276
Research and
development expenses(a)
2,165
1,742
3,830
3,285
Amortization of
intangible assets
783
823
1,598
1,648
Acquisition-related
in-process research and development charges
--
513
283
513
Restructuring
charges and acquisition-related costs
1,051
268
1,863
567
Other
(income)/deductions - net
(487)
(359)
(889)
(615)
Income from
continuing operations before provision for taxes on income and minority
interests
1,619
3,083
5,672
7,353
Provision for
taxes on income
272
790
961
1,052
Minority
interests
Income from
continuing operations
1,345
2,290
4,706
6,296
Discontinued
operations:
Income from
discontinued operations - net of tax
--
108
--
210
Gains/(losses)
on sales of discontinued operations - net of tax
(78)
17
(47)
20
Discontinued
operations - net of tax
(78)
125
(47)
230
Net income
1,267
2,415
4,659
6,526
Earnings per common share - basic:
Income from
continuing operations
0.19
0.31
0.67
0.86
Discontinued
operations - net of tax
(0.01)
0.02
(0.01)
0.03
Net income
0.18
0.33
0.66
0.89
Earnings per common share -
diluted:
Income from
continuing operations
0.19
0.31
0.67
0.86
Discontinued
operations - net of tax
(0.01)
0.02
(0.01)
0.03
Net income
0.18
0.33
0.66
0.89
Weighted-average
shares used to calculate earnings per common share:
Basic
6,966
7,282
7,009
7,298
Diluted
6,990
7,305
7,033
7,330
Cash dividends paid per common
share
0.29
0.24
0.58
0.48
(a)
Exclusive of amortization of
intangible assets, except as disclosed in Note 10B. Goodwill and
Other Intangible Assets: Other Intangible Assets.
See accompanying
Notes to Condensed Consolidated Financial Statements.
PFIZER
INC AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(millions
of dollars)
July 1,
2007*
Dec. 31,
2006**
ASSETS
Cash and cash equivalents
2,138
1,827
Short-term investments
20,115
25,886
Accounts receivable, less allowance
for doubtful accounts
9,497
9,392
Short-term loans
540
514
Inventories
5,734
6,111
Prepaid expenses and taxes
3,564
3,157
Assets of discontinued operations and
other assets held for sale
34
62
Total current assets
41,622
46,949
Long-term
investments and loans
5,067
3,892
Property, plant and equipment, less
accumulated depreciation
16,298
16,632
Goodwill
20,985
20,876
Identifiable
intangible assets, less accumulated amortization
22,902
24,350
Other assets,
deferred taxes and deferred charges
3,529
2,138
Total assets
110,403
114,837
LIABILITIES
AND SHAREHOLDERS' EQUITY
Short-term borrowings, including
current portion of long-term debt
2,432
2,434
Accounts payable
1,845
2,019
Dividends payable
2,010
2,055
Income taxes payable
516
6,466
Accrued compensation and related
items
1,573
1,903
Other current liabilities
6,760
6,510
Liabilities of discontinued operations
and other liabilities held for sale
--
Total current liabilities
15,136
21,389
Long-term debt
5,777
5,546
Pension benefit
obligations
3,389
3,632
Postretirement
benefit obligations
1,955
1,970
Deferred taxes
7,602
8,015
Other taxes
payable
5,426
--
Other
noncurrent liabilities
3,024
2,927
Total liabilities
42,309
43,479
Shareholders' equity
Preferred stock
110
141
Common stock
442
441
Additional
paid-in capital
69,555
69,104
Employee
benefit trust, at fair value
(604)
(788)
Treasury stock
(51,833)
(46,740)
Retained
earnings
50,304
49,669
Accumulated
other comprehensive income/(expense)
120
(469)
Total shareholders' equity
68,094
71,358
Total liabilities and shareholders'
equity
110,403
114,837
* Unaudited.
** Condensed from audited
financial statements.
See accompanying
Notes to Condensed Consolidated Financial Statements.
PFIZER INC AND
SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Six Months
Ended
(millions of dollars)
July 1,
2007
July 2,
2006
Operating
Activities:
Net income
4,659
6,526
Adjustments to
reconcile net income to net cash provided by operating activities:
Depreciation
and amortization
2,712
2,694
Share-based
compensation expense
228
326
Acquisition-related
in-process research and development charges
283
513
Gains on
disposal of investments, products and product lines
(79)
(168)
(Gains)/losses
on sales of discontinued operations
39
(31)
Deferred taxes
from continuing operations
(951)
(438)
Other deferred
taxes
--
45
Other non-cash
adjustments
37
270
Changes in assets
and liabilities (net of businesses acquired and divested)
(2,020)
(633)
Net cash provided by operating
activities
4,908
9,104
Investing Activities:
Purchases of
property, plant and equipment
(757)
(887)
Purchases of short-term
investments
(10,738)
(5,663)
Proceeds from
redemptions of short-term investments
17,101
13,239
Purchases of
long-term investments
(1,243)
(248)
Proceeds from redemptions
of long-term investments
22
47
Purchases of
other assets
(82)
(78)
Proceeds from
sales of other assets
29
Proceeds from
the sales of businesses, products and product lines
14
14
Acquisitions,
net of cash acquired
(463)
(1,989)
Other investing
activities
(336)
(116)
Net cash provided by investing
activities
3,547
4,322
Financing Activities:
Increase in
short-term borrowings, net
78
938
Principal
payments on short-term borrowings
(763)
(10,583)
Proceeds from
issuances of long-term debt
1,243
1,054
Principal
payments on long-term debt
(60)
(2)
Purchases of
common stock
(4,999)
(2,000)
Cash dividends
paid
(4,040)
(3,468)
Stock option
transactions and other
383
318
Net cash used
in financing activities
(8,158)
(13,743)
Effect of exchange-rate
changes on cash and cash equivalents
14
(9)
Net increase/(decrease)
in cash and cash equivalents
311
(326)
Cash and cash
equivalents at beginning of period
1,827
2,247
Cash and cash
equivalents at end of period
2,138
1,921
Supplemental
Cash Flow Information:
Cash paid
during the period for:
Income taxes
3,672
921
Interest
354
414
See
accompanying Notes to Condensed Consolidated Financial Statements.
PFIZER
INC AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of
Presentation
We prepared the condensed
consolidated financial statements following the requirements of the Securities
and Exchange Commission (SEC) for interim reporting. As permitted under those
rules, certain footnotes or other financial information that are normally
required by accounting principles generally accepted in the United States of
America (GAAP) can be condensed or omitted. Balance sheet amounts and operating
results for subsidiaries operating outside the U.S. are as of and for the
three-month and six month periods ended May 27, 2007, and May 28, 2006.
We made certain reclassifications to prior
period amounts to conform to the second-quarter 2007 presentation.
Revenues, expenses, assets and
liabilities can vary during each quarter of the year. Therefore, the results
and trends in these interim financial statements may not be representative of
those for the full year.
We are responsible for the unaudited
financial statements included in this document. The financial statements
include all normal and recurring adjustments that are considered necessary for
the fair presentation of our financial position and operating results.
The information included in this
Quarterly Report on Form 10-Q should be read in conjunction with the
consolidated financial statements and accompanying notes included in Pfizer's
Annual Report on Form 10-K for the year ended December 31, 2006.
Note 2. Adoption of New
Accounting Policy
As of January 1, 2007, we adopted the provisions of Financial Accounting
Standards Board (FASB) Interpretation No. 48 (FIN 48), Accounting for
Uncertainty in Income Taxes, an interpretation of SFAS 109, Accounting for
Income Taxes, and supplemented by FASB Financial Staff Position FIN
48-1, Definition of Settlement in FASB Interpretation No. 48, issued May
2, 2007, and changed our policy related to the accounting for income tax
contingencies. To understand the cumulative effect of these accounting changes,
see Note 6A. Taxes on Income: Adoption of New Accounting
Standard.
We continue to account for income tax
contingencies using a benefit recognition model. Beginning January
1, 2007, if we consider that a tax position is 'more likely than not' of being
sustained upon audit, based solely on the technical merits of the position, we
recognize the benefit. We measure the benefit by determining the amount that is
greater than 50% likely of being realized upon settlement, presuming that the
tax position is examined by the appropriate taxing authority that has full
knowledge of all relevant information. These assessments can be complex and we
often obtain assistance from external advisors.
Under the benefit recognition model, if our initial assessment
fails to result in the recognition of a tax benefit, we regularly monitor our
position and subsequently recognize the tax benefit: (i) if there are changes
in tax law or analogous case law that sufficiently raise the likelihood of
prevailing on the technical merits of the position to more likely than not; (ii)
if the statute of limitations expires; or (iii) if there is a completion of an
audit resulting in a favorable settlement of that tax year with the appropriate
agency.
Liabilities associated with uncertain tax positions are now classified as
current only when we expect to pay cash within the next 12 months. Interest and
penalties, if any, continue to be recorded in Provision for taxes on income
and are classified on the balance sheet with the related tax liability.
Prior to 2007, our policy had been to account for income tax
contingencies based on whether we determined our tax position to be 'probable'
under current tax law of being sustained, as well as an analysis of potential
outcomes under a given set of facts and circumstances. In addition, we
previously considered all tax liabilities as current once the associated tax
year was under audit.
Note 3. Acquisitions
In the first quarter of 2007, we
acquired BioRexis Pharmaceutical Corp., a privately held biopharmaceutical
company with a number of diabetes candidates and a novel technology platform
for developing new protein drug candidates, and Embrex, Inc., an animal health
company that possesses a unique vaccine delivery system known as Inovoject, which
enables baby chicks to be vaccinated while inside their eggs. In connection
with these and other small acquisitions, we recorded $283 million, in Acquisition-related
in-process research and development charges in the first quarter of 2007.
In the second quarter of 2006, we completed the acquisition of all the
outstanding shares of Rinat Neuroscience Corp., a biologics company with
several new central-nervous-system product candidates. In connection with this
and other smaller acquisitions, we recorded $513 million, in Acquisition-related
in-process research and development charges in the second quarter of 2006.
On February 28, 2006, we completed
the acquisition of the sanofi-aventis worldwide rights, including patent rights
and production technology, to manufacture and sell Exubera, an inhaled form of
insulin for use in adults with type 1 and type 2 diabetes, and the
insulin-production business and facilities located in Frankfurt, Germany,
previously jointly owned by Pfizer and sanofi-aventis, for approximately $1.4 billion
(including transaction costs). In 2006, in connection with the acquisition, as
part of our final purchase price allocation, we recorded $1.0 billion of
developed technology rights, $218 million of inventory and $166 million
of Goodwill, all of which have been allocated to our Pharmaceutical segment.
The amortization of the developed technology rights is primarily included in Cost
of sales. Prior to the acquisition, in connection with our collaboration
agreement with sanofi-aventis, we recorded a research and development milestone
due to us from sanofi-aventis of $118 million ($71 million, after
tax) in the first quarter of 2006 in Research and development expenses
upon the approval of Exubera in January 2006 by the Food and Drug
Administration (FDA).
Note 4. Discontinued
Operations
The following amounts, primarily related
to our Consumer Healthcare business which was sold in December 2006 for $16.6 billion,
have been segregated from continuing operations and included in Discontinued
operations - net of tax in the condensed consolidated statements of income:
Three
Months Ended
Six
Months Ended
(millions
of dollars)
July 1,
2007
July 2,
2006
July 1,
2007
July 2,
2006
Revenues
--
1,027
--
1,946
Pre-tax income
--
160
--
315
Provision for
taxes on income
--
(52)
--
(105)
Income from operations
of discontinued businesses - net of tax
--
108
--
210
Pre-tax gains/(losses) on sales of
discontinued businesses
(79)
26
(39)
31
Provision for taxes on gains
(9)
(8)
(11)
Gains/(losses)
on sales of discontinued operations - net of tax
(78)
17
(47)
20
Discontinued operations - net of
tax
(78)
125
(47)
230
For a period of time, we will
continue to generate cash flows and to report income statement activity in
continuing operations that are associated with our former Consumer Healthcare
business. The activities that give rise to these impacts are transitional in
nature and generally result from agreements that ensure and facilitate the
orderly transfer of business operations to the new owner. Included in
continuing operations for the second quarter of 2007 were the following amounts
associated with these transition service agreements that will no longer occur
after the full transfer of activities to the new owner: Revenues of $50 million;
Cost of sales of $45 million; Selling, informational and
administrative expense of $5 million; and Other
(income)/deduction-net of $7 million in income, and for the first six
months of 2007: Revenues of $94 million; Cost of sales of $80 million;
Selling, informational and administrative expense of $7 million; and
Other (income)/deduction-net of $9 million in income.
Note 5. Adapting to
Scale Productivity Initiative
We incurred the following costs in
connection with our Adapting to Scale (AtS) productivity initiative, which was launched
in early 2005 and broadened in October 2006:
Three
Months Ended
Six
Months Ended
(millions
of dollars)
July 1,
2007
July 2,
2006
July 1,
2007
July 2,
2006
Implementation
costs(a)
317
180